# Marianne Bjordal

> Marianne Bjordal is a seed investor at 3B Future Health Fund backing Biotechnology and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [3B Future Health Fund](https://shizune.co/investors/profile/helsinn-investment-fund)
- Location: Nice, France
- Total investments: 4
- Last investment: Sep 2024
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/mariannebjordalganot/
- X (Twitter): https://twitter.com/mariannebjordal
- Website: https://x.com/mariannebjordal

Marianne Bjordal is a seed investor at 3B Future Health Fund in Nice focused on Biotechnology and Medical. Marianne Bjørdal joined 3B Future Health Fund in 2018 where she is a partner. She has more than 15 years experience in research and early stage investment. Prior to joining 3B Future Health, Marianne worked as a researcher for the French National Centre for Scientific Research (CNRS). She is a former Marie Curie Early-Stage Researcher and wasawarded the AXA Prize from the French Academy of Science in 2014. Marianne received an M.Sc. in Molecular Biology from the University of Bergen in Norway, a Ph.D. in Molecular and Cellular Biology from the University of Nice in France and an MBA from the IAE Nice Graduate School of Management, France.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Medical | 1 | 25% |
| Genetics | 1 | 25% |
| Biopharma | 1 | 25% |
| Health Care | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 25% |
| Series A | 1 | 25% |
| Series B | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Italy | 1 | 25% |
| United Kingdom | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Epsilogen | IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $16.3M | Series B | Sep 09, 2024 |  |
| Sibylla Biotech | Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas. | $23M | Series A | Oct 04, 2022 |  |
| Epsilogen | IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $41.2M | Series B | Mar 02, 2022 |  |
| GenEp | GenEp, Inc. is a pre-clinical stage biotechnology company based on intellectual property assets. GenEp creates therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment-resistant epilepsies. | $1.5M | Seed | Oct 26, 2021 |  |

4 of 4 investments shown.

## Co-investors
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 3 deals together
- [ALSA Ventures](https://shizune.co/investors/profile/alsa-ventures) — VC Fund, 2 deals together
- [British Patient Capital](https://shizune.co/investors/profile/british-patient-capital) — VC Fund, 2 deals together
- [Epidarex Capital](https://shizune.co/investors/profile/epidarex-capital) — VC Fund, 2 deals together
- [Angelini Lumira Biosciences Fund](https://shizune.co/investors/profile/angelini-lumira-biosciences-fund) — VC Fund, 1 deal together
- [Caribou Property](https://shizune.co/investors/profile/caribou-property) — VC Fund, 1 deal together

## About 3B Future Health Fund

VC Fund · Monaco, Germany

Helsinn Investment Fund S.A. is a Luxembourg fund focused on early-stage investments in areas of high unmet patient need.

5 contacts available at 3B Future Health Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Carlos von Bonhorst | Strategic Consultant | https://shizune.co/investors/profile/carlos-von-bonhorst |
| Marianne Bjordal | Partner | https://shizune.co/investors/profile/marianne-bjordal |
| Riccardo Braglia | Vice Chairman and Chief Executive Officer | https://shizune.co/investors/profile/riccardo-braglia |
| Francesco Granata | Consultant | https://shizune.co/investors/profile/francesco-granata |
| Karin Hehenberger | Medical and Scientific Consultant | https://shizune.co/investors/profile/karin-hehenberger |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Marianne Bjordal invest in?

Marianne Bjordal invests primarily in Biotechnology, Medical and Genetics startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Marianne Bjordal last invest?

The most recent investment recorded for Marianne Bjordal closed in Sep 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co